Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and GM-CSF in Unresectable Stage IIIC/IV Melanoma
NCT02009397Phase 2Completed
- Sponsor
- University of Louisville
- Start
- Feb 2012
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, sargramostim in melanoma, sponsored by University of Louisville. Started Feb 2012; status: completed.
02
Drugs
ipilimumabsargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02009397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009397.